Identification of Potential Drug Targets for Antiplatelet Therapy Specifically Targeting Platelets of Old Individuals through Proteomic Analysis

• Published in: Biomedicines Vol. 11; no. 11; p. 2944
• Main Authors: Lee, Seung Hee, Cho, Suyeon, Lee, Jong Youl, Hong, Jung Yeon, Kim, Suji, Jeong, Myong-Ho, Kim, Won-Ho
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.10.2023
• Subjects: Acids; aging; Anticoagulants (Medicine); antiplatelet therapy; Blood platelets; COVID-19; Diabetes; Disease; Enzymes; Geriatrics; Health aspects; Membrane proteins; Mortality; Older people; Peptides; Platelets; Population; Proteins; Proteomes; Proteomics; Scientific equipment and supplies industry; Software; Solvents; Therapeutic targets; Thromboembolism; Thrombosis; United States; United States > US
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines11112944

Aging is a growing problem worldwide, and the prevalence and mortality of arterial and venous thromboembolism (VTE) are higher in the elderly than in the young population. To address this issue, various anticoagulants have been used. However, no evidence can confirm that antithrombotic agents are suitable for the elderly. Therefore, this study aims to investigate the platelet proteome of aged mice and identify antithrombotic drug targets specific to the elderly. Based on the proteome analysis of platelets from aged mice, 308 increased or decreased proteins were identified. Among these proteins, three targets were selected as potential antithrombotic drug targets. These targets are membrane proteins or related to platelet function and include beta-2-glycoprotein 1 (β2GP1, ApolipoproteinH (ApoH)), alpha-1-acid glycoprotein2 (AGP2, Orosomucoid-2 (Orm2)), and Ras-related protein (Rab11a).